Development and calibration of a mathematical model of HIV outcomes among Rwandan adults: informing equitable achievement of targets in Rwanda

April D. Kimmel^{1,2}, Zhongzhe Pan¹, Ellen Brazier³, Gad Murenzi⁴,

Benjamin Muhoza⁴, Marcel Yotebieng⁵, Kathryn Anastos⁵, Denis Nash^{3,6}, and on

behalf of the Central Africa International epidemiology Databases to Evaluate AIDS (CA-

IeDEA)

¹ Department of Health Policy, Virginia Commonwealth University School of Public Health, Richmond, USA. ² Division of Infectious Diseases, Department of Internal Medicine, Virginia Commonwealth University School of Medicine, Richmond, USA. ³ Institute for Implementation Science in Population Health, City University of New York, USA. ⁴ Research for Development (RD Rwanda), Kigali, Rwanda. ⁵ Albert Einstein College of Medicine, New York, USA. ⁶ Department of Epidemiology and Biostatistics, City University of New York Graduate School of Public Health, USA.

Research reported in this publication was supported by the U.S. National Institutes of Health's National Institute of Allergy and Infectious Diseases, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, the National Cancer Institute, the National Institute of Mental Health, the National Institute on Drug Abuse, the National Heart, Lung, and Blood Institute, the National Institute on Alcohol Abuse and Alcoholism, the National Institute of Diabetes and Digestive and Kidney Diseases, and the Fogarty International Center under

Award Number U01AI096299. Informatics resources are supported by the Harmonist project under Award Number R24AI24872.

This work was presented in part at the 25th International Workshop on HIV and Hepatitis

Observational Databases (IWHOD), Athens, Greece, March 23 – 25, 2023.

Corresponding author:

April D. Kimmel, PhD

Department of Health Policy, School of Population Health

Virginia Commonwealth University

Box 480530

Richmond, VA USA 23280

Word count: 4,454

1 ABSTRACT

- 2 Background: We developed and calibrated the Central Africa-International epidemiology
- 3 Databases to Evaluate AIDS (CA-IeDEA) HIV policy model to inform equitable achievement of
- 4 global goals, overall and across sub-populations, in Rwanda.
- 5 **Methods:** We created a deterministic dynamic model to project adult HIV epidemic and care
- 6 continuum outcomes, overall and for 25 subpopulations (age group, sex, HIV acquisition risk,
- 7 urbanicity). Data came from the Rwanda cohort of CA-IeDEA, 2004–2020; Rwanda
- 8 Demographic and Health Surveys, 2005, 2010, 2015; Rwanda Population-based HIV Impact
- 9 Assessment, 2019; and the literature and reports. We calibrated the model to 47 targets by
- 10 selecting the 50 best-fitting parameter sets among 20,000 simulations. Calibration targets
- 11 reflected epidemic (HIV prevalence, incidence), global goals (percentage on antiretroviral
- 12 therapy (ART) among diagnosed, percentage virally suppressed among on ART) and other
- 13 (number on ART, percentage virally suppressed) indicators, overall and by sex. Best-fitting sets
- 14 minimized the summed absolute value of the percentage deviation (AVPD) between model
- 15 projections and calibration targets. Good model performance was mean AVPD \leq 5% across the
- 16 50 best-fitting sets and/or projections within the target confidence intervals; acceptable was mean
- 17 AVPD >5% and $\leq 15\%$.
- 18 **Results:** Across indicators, 1,841 of 2,350 (78.3%) model projections were a good or acceptable
- 19 fit to calibration targets. For HIV epidemic indicators, 256 of 300 (85.3%) projections were a
- 20 good fit to targets, with the model performing better for women (83.3% a good fit) than for men
- 21 (71.7% a good fit). For global goals indicators, 96 of 100 (96.0%) projections were a good fit;
- 22 model performance was similar for women and men. For other indicators, 653 of 950 (68.7%)
- 23 projections were a good or acceptable fit. Fit was better for women than for men (percentage
- virally suppressed only) and when restricting targets for number on ART to 2013 and beyond.
- 25 **Conclusions**: The CA-IeDEA HIV policy model fits historical data and can inform policy
- 26 solutions for equitably achieving global goals to end the HIV epidemic in Rwanda. High-quality,
- 27 unbiased population-based data, as well as novel approaches that account for calibration target
- 28 quality, are critical to ongoing use of mathematical models for programmatic planning.

29 INTRODUCTION

| 30 | Rwanda, a Central African country with a generalized HIV epidemic (HIV prevalence = |
|----|--|
| 31 | 3%) [1, 2], is accelerating toward achieving the 95-95-95 global targets and ending the public |
| 32 | health threat posed by HIV epidemic by 2030 [3]. Recent data have generated optimism, with |
| 33 | 97.5% of diagnosed Rwandan adults receiving antiretroviral therapy (ART) and 90.1% of |
| 34 | Rwandan adults on ART having achieved HIV viral suppression [1]. However, Rwanda's |
| 35 | success is tempered by data suggesting lower HIV awareness (83.8% from population-based |
| 36 | survey estimates); worse care continuum outcomes among men, adolescents and young adults; |
| 37 | and notable HIV acquisition risk among rural populations [1, 4], which will impede continued |
| 38 | progress and perpetuate existing disparities in achieving global targets. |
| 39 | Mathematical models are a tool commonly used to evaluate potential policy solutions |
| 40 | addressing advancement toward epidemic control and health equity. For Rwanda, these models |
| 41 | have been used to understand the distribution of new HIV infections [5]; evaluate the impact of |
| 42 | HIV prevention policies on epidemic outcomes overall and among key population (i.e., female |
| 43 | sex workers and their male clients) [6, 7]; forecast improvements along the care continuum on |
| 44 | overall mortality among people with HIV [8]; and project achievement of behavioral and |
| 45 | treatment targets on HIV transmission dynamics [9]. |
| 46 | While the existing literature has used mathematical models primarily to assess the impact |
| 47 | of different strategies on epidemic indicators, no mathematical models applied to Rwanda, to our |
| 48 | knowledge, have examined potential policy solutions for achieving all global targets and |
| 49 | promoting equity in achieving these targets across sub-populations. We aimed to develop and |

50 calibrate the Central Africa-International epidemiology Databases to Evaluate AIDS (CA-

51 IeDEA) HIV policy model. IeDEA is an international research consortium that has collected and

| 52 | harmonized globally diverse observational data for over 2 million people living with HIV and |
|----|---|
| 53 | enrolling in HIV care since 2004. The Rwanda cohort of CA-IeDEA comprises over 30,000 ever |
| 54 | enrolled in HIV care at 12 clinics. It is thus a rich data source with which to populate |
| 55 | mathematical models used to examine relevant, real-world policy solutions. |
| 56 | |
| 57 | MATERIALS AND METHODS |
| 58 | Overview |
| 59 | We developed the CA-IeDEA HIV policy model, a deterministic dynamic compartmental |
| 60 | model that projects HIV epidemic and care continuum outcomes. After model implementation, |
| 61 | instantiation and parameterization, we calibrated the model to historical data, selected the best- |
| 62 | fitting sets of model parameters, and evaluated the model's performance. Model parameters and |
| 63 | calibration targets were based on individual-level data from the Rwanda cohort of CA-IeDEA |
| 64 | [10, 11], as well as Rwandan national surveys [12-14], international databases [15] and the |
| 65 | literature (see Table 1). Secondary data were accessed 7 April 2022; the authors did not have |
| 66 | access in the data to readily identifiable information that could identify individual participants. |
| 67 | The model was implemented in R version 4.2.1 (R Core Team, 2022). Additional details are in |
| 68 | the Supplement. |
| 69 | CA-IeDEA HIV policy model |
| 70 | Overall structure |
| 71 | The CA-IeDEA HIV policy model is an extended Susceptible-Infected-Removed (SIR) |
| 72 | dynamic epidemic model, adapted from previous work [16]. The model includes a susceptible |
| 73 | compartment, 24 mutually exclusive infectious compartments and a death compartment (|

| 74 |). The susceptible compartment includes the population at risk of acquiring HIV. |
|----|---|
| 75 | Infectious compartments capture HIV disease progression and steps along the HIV care |
| 76 | continuum. We characterize HIV disease progression according to different CD4 cell count strata |
| 77 | (>500, 351–500, 201–350 and <200 cells/mm ³) that reflect key thresholds for the risk of HIV- |
| 78 | related opportunistic infections and other illnesses [17]. They also correspond to international |
| 79 | and Rwandan recommendations on CD4-based thresholds for antiretroviral therapy (ART) |
| 80 | initiation over time [18-24]. We did not explicitly model acute HIV, given its small window of |
| 81 | detection (approximately 14 days) that is captured in a single model time step (see below). |
| 82 | |
| | |

83 Fig 1. Model schematic of the CA-IeDEA HIV policy model 84 S=Susceptible compartment; I=Infectious compartments; D=Death compartments; ART=antiretroviral.85 Shown is a simplified schematic of the CA-IeDEA HIV policy model. Each modeled population enters the 86 susceptible compartment, can probabilistically transition to and move between infectious compartments and can 87 probabilistically transition to the death compartment, with transitions and their directionality denoted by arrows. 88 Infectious model compartments are outlined by the dotted line and represent the combination of degree of HIV 89 disease progression (i.e., CD4 cell count strata) and engagement in HIV care; disease progression for those on ART 90 represents the CD4 cell count stratum at ART initiation. Each model compartment includes 25 sub-populations 91 partitioned by age, sex, risk of acquisition and urbanicity (sub-populations not shown).

92

93 The HIV care continuum is defined as key steps along the care cascade: undiagnosed, 94 diagnosed, linked to care, on ART and virally suppressed, on ART and not virally suppressed, 95 and lost to follow-up. We explicitly modeled linkage to care due to historical delays in ART 96 initiation [25, 26], including rapid ART initiation (e.g., within 7 days), after linkage to care [21, 97 25, 26]. We did not explicitly model on-ART disease progression to maintain model parsimony 98 and given successful calibration of other similarly structured HIV policy models [16, 27]. Death 99 occurs from background mortality and HIV-related causes, with transitions to the death 100 compartment occurring only from infectious compartments. There is no transition from the 101 susceptible to the death compartment as changes in the size of the susceptible population over 102 time reflect background mortality.

Model dynamics are expressed using a system of ordinary differential equations. The differential equations are implemented as difference equations in order to project outcomes at discrete time points [28], which is important for informing policy decisions, and also to reduce computational complexity during the model calibration process. Movement between compartments occurs based on a one-month time step, which captures clinically meaningful events related to disease progression and engagement in care.

109 Study population partitions

110 The model is partitioned into 25 sub-populations by age, sex, risk and subnational unit 111 (i.e., urbanicity) to account for differences in HIV acquisition risk and steps along the care 112 continuum, resulting in a total of 650 model compartments (25 sub-populations x 26 113 compartments). Age is partitioned into five groups (i.e., 15–24, 25–34, 35–44, 45–54, 55+ years) 114 given age-related differences in HIV prevalence and HIV testing [29-32]. Women are 115 represented as having either lower or higher HIV acquisition risk, with the latter representing 116 female sex workers (FSWs) who have higher HIV prevalence (45.8% compared to 3.6% among 117 low-risk women) and lower viral suppression (71% compared to 79% among lower-risk women) 118 [33]. Men are considered lower risk. We do not explicitly include male clients of female sex 119 workers as a higher risk sub-population, given the HIV acquisition risk for male clients of female 120 sex workers is similar to non-clients [29-31]. Subnational units are applied as an urban-rural 121 classification because HIV prevalence in urban areas in Rwanda is more than double that of rural 122 areas [21]. However, we did not partition women who were at higher risk of HIV acquisition 123 (i.e., FSWs) by urbanicity given more than 80% reside in urban areas [34].

124 Force of infection

125 The force of infection, or the probability of HIV acquisition in different susceptible sub-126 populations, is based on heterosexual contact. We calculate the force of infection using: the per-127 act HIV transmission probability in the absence of condoms and HIV treatment, the probability 128 of condom use, the probability of having a virally suppressed partner, the reduction in HIV 129 acquisition risk due to condom use or having a virally suppressed partner, the probability of 130 sexual contact with a specific sub-population, the probability of a sexual partner with HIV within 131 a sub-population, and the number of sex acts per month. We assume no sexual contact between 132 lower risk populations living in urban and in rural areas due to relatively low spatial mobility in 133 Rwanda [35]; however, FSWs have sexual contact with sub-populations living in either urban or 134 rural areas. We apply random mixing across sub-populations with sexual contacts given our 135 assumption that all sub-populations are sexually active and randomly choose their sexual 136 partners, including FSWs. 137 **Model inputs** 138 Instantiation

139 Model instantiation involved distributing the total population across sub-populations and 140 by HIV status, disease progression and care engagement (**Table 1**). In the current study, the 141 initial distribution was applied to the overall Rwandan adult population 15–64 years in 2004, the 142 first year in the historical projection period used for the calibration process. We determined the 143 total number in each sub-population based on population projections and the literature specific to 144 Rwanda [15, 36], estimating the number of people living with HIV in a given sub-population 145 from national survey data on HIV prevalence (Demographic and Health Survey (DHS) Rwanda, 146 2005; Behavioral and Biological Surveillance Survey (BBSS), 2010) [12, 37].

Table 1. Key model parameters and calibration targets

| | Baseline value(s) ^a | Data source(s) |
|--|--------------------------------|---|
| Panel A. Parameters | | |
| Model instantiation | | |
| Total population | 4,729,488 | World Bank [15] |
| Population size of female sex workers | 12,278 | UNAIDS [36] |
| HIV prevalence, by sub-population | 0.27%-63% | DHS Rwanda (2005) [12], BBSS (2010) [37] |
| Proportions along the care continuum, by sub-population and CD4 stratum ^a | 0-85% | CA-IeDEA (Rwanda, 2004) [11] |
| Force of infection | | |
| Probability of HIV transmission per sex act | 0.0005-0.0087 | Boily (2009) [39] |
| Proportion consistently using condoms | 4%-62% | DHS Rwanda (2005, 2010, 2015) [12-14], BBSS (2010) [37] |
| Effectiveness of condoms | 0.80 | Weller (2002) [40] |
| Effectiveness of viral suppression on HIV transmission | 0.966 | Supervie (2014) [41] |
| Number of sex acts | 1–40 | Braunstein (2011a) [42] |
| Transition probabilities (monthly) for infectious compartments | | |
| Susceptible population growth rates | 0.09%-0.45% | World Bank [15] |
| Natural history disease progression, by sex | 0.008-0.099 | CA-IeDEA (Rwanda, 2004–2020) [11] |
| Diagnosis, by CD4 stratum and year | 0.016-0.241 | DHS Rwanda (2005, 2010, 2015) [12-14], Okal (2017) [43] |
| Linkage to care, by CD4 stratum and year | 0.075-0.207 | Nsanzimana (2015) [44], Braunstein (2011b) [38], Okal (2017) [43] |
| Loss to follow-up, by CD4 stratum and ART status | 0.011-0.021 | CA-IeDEA (Rwanda, 2004–2020) [11] |
| On ART and virally suppressed, by CD4 stratum and year | 0.003-0.148 | CA-IeDEA (Rwanda, 2004–2020) [11] |
| ART failure, by CD4 stratum | 0.001-0.002 | CA-IeDEA (Rwanda, 2004–2020) [11] |
| Re-engagement in care ^b | 0.023 | CA-IeDEA (Rwanda, 2004–2020) [11] |
| Death on ART and virally suppressed, by sub-population and CD4 stratum ^b | 0.0002-0.017 | CA-IeDEA (Rwanda, 2004–2020) [11] |
| Panel B. Calibration targets | | |
| HIV epidemic | | |
| HIV prevalence (15–44 years), overall and by sex and year | 0.018-0.037 | DHS Rwanda (2005, 2010, 2015) [12-14], RPHIA (2019) [1] |
| HIV prevalence (15–64 years), overall and by sex | 0.022-0.037 | RPHIA (2019) [1] |
| HIV incidence (15–44 years), overall and by sex | 0.0006-0.0010 | RPHIA (2019) [1] |
| Global goals | | |
| % on ART among diagnosed (15–44 years), overall and by sex | 96.2%-97.2% | RPHIA (2019) [1] |
| % virally suppressed among on ART (15-44 years), overall and by sex | 75.9%-89.9% | RPHIA (2019) [1] |
| Other | | |
| % virally suppressed among diagnosed (15-44 years), overall and by sex | 61.3%-76.5% | RPHIA (2019) [1] |
| % virally suppressed among diagnosed (15-64 years), overall and by sex | 66.8%-77.2% | RPHIA (2019) [1] |
| Number on ART (15–44 years), overall | 6,356-197,544 | Rwanda National Report [45] |

Abbreviations: UNAIDS=Joint United Nations Programme on HIV/AIDS; DHS=Demographic and Health Survey; BBSS=Behavioral and Biological Surveillance Survey; CA-IeDEA= Central Africa International epidemiology Databases to Evaluate AIDS; RPHIA= Rwanda Population-Based HIV Impact Assessment.

^a The baseline value(s) reporting a range represent the range of baseline parameter values or calibration targets across all sub-populations and years. The parameter values and calibration targets, overall and for each sub-population, are reported separately in the supplementary material.

For each infectious compartment of a given sub-population, the initial population was calculated based on the proportion living with HIV in each step of the HIV care continuum and in each CD4 stratum. These proportions were estimated using individual-level longitudinal data on HIV treatment and care from the Rwanda cohort of CA-IeDEA [11], as well as national surveys (DHS Rwanda 2005) [12] and the literature [38].

153 Parameterization

154 Model parameterization involved deriving parameters, by sub-population, for susceptible 155 population growth, force of infection, and monthly transition probabilities between 156 compartments (Table 1). We assumed that the monthly population growth rate applied to the 157 susceptible compartments was equal to the total population growth rate, which we estimated as 158 the simple average of the Rwanda's monthly population growth rate, 2004–2020, from World 159 Bank population projections [15]. Parameter values for the force of infection were generally 160 extracted from literature synthesizing existing evidence from sub-Saharan African countries or 161 surveys conducted in Rwanda, with the proportion using condoms estimated directly from DHS 162 Rwanda (2005, 2010, 2015) for the lower risk population and from the BBSS report for FSWs 163 [12-14, 37].

For all sub-populations except FSWs, transition probabilities for natural history disease
progression, HIV viral suppression, ART failure, loss to follow-up, care re-engagement and
death were derived from the Rwanda cohort of CA-IeDEA, 2004–2020 [11], while those for HIV
diagnosis and linkage to care were estimated from DHS Rwanda (2005, 2010, 2015) and
extracted from the literature [12-14, 44], respectively. We defined HIV viral suppression as
individuals on ART without evidence of virologic failure, which was at least one post-ART
initiation follow-up HIV viral load test result ≥1000 copies/mL [24]. We defined loss to follow-

up as at least 365 days between the last clinic visit and last contact (among those on ART) or at
least 6 months between the most recent clinic visit and last contact (pre-ART) [43, 46]. Monthly
probabilities of death accounted for misclassification of loss to follow-up both on and off ART
[47, 48].

For FSWs, transition probabilities for diagnosis, linkage to care and condom use were extracted from existing literature and government reports [38, 39, 41]. When transition probabilities for loss to follow-up and re-engagement in this sub-population were unavailable, we applied the baseline values used for the lower risk female population but applied wider confidence bounds to account for the uncertainty in the parameter value.

180 Model calibration

181 We calibrated model parameter values in order to fit model projections to historical data. 182 The process involved identifying calibration targets, generating and selecting best-fitting sets of 183 model parameters, and assessing the model's performance.

184 *Calibration targets*

185 We selected 47 calibration targets reflecting HIV epidemic, global goals and other care 186 engagement indicators for adults 15–44 years and 15–64 years, overall and/or by sex, over a 16-187 year historical calibration period between 2004 and 2020 (Table 1). HIV epidemic targets 188 included HIV prevalence and HIV incidence and came from DHS (Rwanda, 2005, 2010, 2015) 189 and RPHIA (2019) [1, 29-31]. Global goals targets included the percentage on ART among 190 adults diagnosed with HIV and percentage virally suppressed among adults on ART (RPHIA, 191 2019) [1]. We did not include global goals targets for youth 15–24 years due to small sample 192 sizes in available survey data. Finally, other targets included the percentage virally suppressed 193 among adults living with HIV (RPHIA, 2019) and the number of adults on ART (Rwanda

194 National HIV Report, 2020) [1, 45]. Because available data report all Rwandans on ART,

195 including pediatric cases, we estimated the number of adults on ART as the product of the total

- 196 reported number on ART and the proportion reported on ART within a given age group (e.g.,
- 197 15–44 years) among total population on ART [45].
- 198 Selecting best-fitting sets of model parameters

199 To select best-fitting parameter sets, we first generated sets of model parameters. We 200 assigned distributions to all model parameters, with the exception of the population size for each 201 sub-population and the proportions of people living with HIV by CD4 stratum given these 202 parameters are single point estimates. We assigned the normal distribution to the susceptible 203 population growth rate; beta distributions to transition probabilities, except the probabilities of 204 linkage to care due to limited information on sample size; and triangular distributions to model 205 parameters that lacked information on their distribution. Across relevant parameters, we then 206 performed a random draw of each parameter's value from its distribution in order to generate a 207 parameter set. We applied random draws to the over 1,500 model parameters and generated 208 20,000 randomly selected parameter sets to fully capture variability across model parameters. 209 Each parameter set was then used to project historical model outcomes associated with the set. 210 We selected the best-fitting sets of model parameters by examining their goodness of fit 211 (GoF), a measure quantifying the difference between the model's projected outcomes and 212 calibration targets. No standard GoF measure(s) exists and thus GoF is defined according to a 213 given model structure and selected calibration targets [49]. In the current analysis, the GoF 214 measure was defined as the summed absolute value of the percentage deviation (sAVPD) 215 between the model's projected outcomes and the calibration targets, with the sAVPD a scale-216 independent measure selected to standardize differences in the units of analysis across calibration

- 217 targets [50, 51]. A smaller sAVPD value represents a smaller overall difference between model
- 218 projections and the historical data, indicating a better model fit. The 50 sets that minimized the
- sAVPD were considered the best-fitting sets of model parameters.
- 220 Performance of the calibrated model

221 Model performance was evaluated according to the percentage of model projections 222 considered good or acceptable. 'Good' model performance was a mean AVPD <5% between the 223 model's projected outcomes and the calibration target(s) across the top 50 best-fitting parameter 224 sets, while 'acceptable' performance was defined as a mean AVPD >5% and <15% [52, 53]. If a 225 model projection was with a given target's confidence intervals, performance was also 226 considered 'good' regardless of the mean AVPD. Among model projection(s) considered 'good', 227 visual trend(s) were required to reflect trends in the historical data, although this was a subjective 228 assessment and only occurred if sufficient targets were available. Model performance was 229 evaluated separately for HIV epidemic indicators, global goals indicators and other indicators.

230

231 **RESULTS**

232 HIV epidemic indicators

For the overall adult population (15–44 and 15–64 years), we compared 300 model projections for HIV epidemic indicators to the calibration targets (50 projections/target x 6 targets=300). Among these 300, 256 (85.3%) were a good fit to calibration targets and 23 (7.6%) an acceptable fit (**Fig 2**). For HIV prevalence indicators only (5 targets), 216 (86.4%) projections were a good fit to calibration targets and 23 (9.2%) were an acceptable fit. Model performance worsened when fitting to targets in 2019, with at least 47 (94.0%) projections a good fit for 2005, 2010 and 2015 targets, but less than 32 (64.0%) projections a good fit to 2019 targets. For the

HIV incidence indicator only (1 target), 50 (100%) projections were good fit to the calibration

- targets; assessing trends over time was not possible given only a single target.
- 242

243 Fig 2. Model projections and HIV epidemic calibration targets for 15-44 year-olds in Rwanda, 2004-2020. 244 Abbreviation: DHS=Demographic Health Survey; RPHIA=Rwanda Population-based Health Impact Assessment 245 The blue line and light blue shades represent the mean and range of the model projections, respectively, using the 50 246 best-fitting parameter sets. The points and the error bar represent the point estimates and 95% confidence interval of 247 the calibration targets, with targets from DHS Rwanda data in purple and targets from RPHIA in red. (A) For HIV 248 prevalence indicators, 80.9% of model projections have good or acceptable fit to calibration targets, with model 249 performance better for women than for men particularly later in the calibration period. (B) For HIV incidence, 100% 250 of model projections have a good fit, which is consistent for women and men.

251

252 For the adult female and male sub-populations (15-44 and 15-64 years), we examined 253 300 model projections each for women and for men (50 projections/target x 6 targets=300 for 254 each sub-population). The model performed better for women than for men, with 250 (83.3%) 255 and 215 (71.7%) projections having a good fit, respectively (Fig 2). An additional thirteen 256 projections for women were an acceptable fit, but none for men. For HIV prevalence indicators 257 only, 200 (80.0%) projections for women and 165 (66.0%) for men were a good fit. Model 258 performance was consistently good (\geq 96% good fit) for women 15-44 years over time; however, 259 performance varied for men in this age group, with over 80% of projections a good fit in 2005 260 and 2015, but only 8 (16.0%) a good fit in 2019. In contrast, among the population age 15–64 261 years, the model performed better for men (68.0% of projections a good fit) compared to women 262 (10.0% of projections a good fit and 22% an acceptable fit). For the HIV incidence indicator, 50 263 (100%) projections were a good fit to calibration targets for both women and men. 264 **Global goals indicators** 265 For the overall adult population (15–44 years), we examined 100 model projections for

266 global goals indicators (50 projections/target x 2 targets=100) (**Fig 3, Panels A and B**). Among

these 100, 96 (96.0%) projections were a good fit and 4 (4.0%) were acceptable. For the

percentage on ART among adults diagnosed with HIV (1 target), 50 (100.0%) projections were a

| 269 | good fit to calibration targets. Visually, the projected percentages decreased in both 2005 and |
|---|--|
| 270 | 2011, but had sharp increases to reflect trend in the subsequent projection periods. For |
| 271 | percentage virally suppressed among adults on ART (1 target), 46 (92.0%) projections were |
| 272 | good fit to targets with an additional 4 (8.0%) projections being acceptable. |
| 273 | |
| 274 275 276 277 278 279 280 281 282 | Fig 3. Model projections and global goals calibration targets for 15–44 year-olds in Rwanda, 2004–2020 <i>Abbreviation: DHS=Demographic Health Survey; RPHIA=Rwanda Population-based Health Impact Assessment</i> The blue line and light blue shades represent the mean and range of the model projections, respectively, using the 50 best-fitting parameter sets. The points and the error bar represent the point estimates and 95% confidence interval of the calibration targets, with targets from DHS Rwanda data in purple and targets from RPHIA in red. (A) For the percentage on ART among diagnosed adults, 100% of model projections had good fit to calibration targets. (B) For the percent virally suppressed among adults on ART, 92% of model projections had a good fit. (C) For the number of adults on ART, 28% of model projections had a good fit. |
| 283 | For the adult female and male sub-populations (15–44 years), we examined 100 |
| 284 | projections each for women and for men (50 projections/target x 2 targets=100 for each sub- |
| 285 | population). Here, 98 (98.0%) and 94 (94.0%) projections were good fit for women and men, |
| 286 | respectively. Two additional projections were acceptable for women and six for men. For |
| 287 | percentage on ART among adults diagnosed with HIV, 50 (100%) projections were good fit to |
| 288 | calibration targets for both women and men. For percentage virally suppressed among adults on |
| 289 | ART, model performance is slightly better for women than men, with 48 (96.0%) and 44 |
| 290 | (88.0%) being good fit to calibration targets, respectively. |
| 291 | Other indicators |
| 292 | For the overall adult population (15-44 and 15-64 years), we examined projections for |
| 293 | the number on ART (50 projections/target x 18 targets=850) and the percentage virally |
| 294 | suppressed among the diagnosed adult population with HIV (50 projections/target x 2 |
| 295 | targets=100). For number on ART, 573 (67.4%) projections were good or acceptable fit with |

| 296 | two-fifths of these projections a good fit (Fig 4). Model fit for the number on ART improved |
|--|--|
| 297 | when restricting the targets to years 2013 and beyond (8 targets), where 369 (92.3%) were good |
| 298 | or acceptable. For the percentage virally suppressed, 80 (80.0%) projections had a good or |
| 299 | acceptable fit with less than one-fifth of these projections considered a good fit. Here, the model |
| 300 | performed better among adults age 15-64 years (94.0% of projections a good or acceptable fit) |
| 301 | than adults age 15–44 years (67.0% of projections a good or acceptable fit). |
| 302 | |
| 303 304 305 306 307 308 309 310 | Fig 4. Model projections and other calibration targets for 15–44 year-olds in Rwanda, 2004–2020 <i>Abbreviation: RPHIA=Rwanda Population-based Health Impact Assessment</i> The blue line and light blue shades represent the mean and range of the model projections, respectively, using the 50 best-fitting parameter sets. The points and the error bar represent the point estimates and 95% confidence interval of the calibration targets, with targets from DHS Rwanda data in purple and targets from RPHIA in red (A) For the number of adults on ART, 28% of model projections had a good fit. (B) For the percentage virally suppressed among adults living with HIV, 65% of model projections had good or acceptable fit to calibration targets. |
| 311 | For the adult female and male sub-populations (15–44 and 15–64 years), we examined |
| 312 | 100 model projections each for women and men on percentage virally suppressed among people |
| 313 | with HIV (50 projections/target x 2 targets=100 for each sub-population). Here, 77 (77%) |
| 314 | projections for women and 54 (54%) for men had good or acceptable fit. For both age ranges, a |
| 315 | smaller proportion of projections had a good fit for women (less than 5%) than for men (20%- |
| 316 | 40%). Model fit for number on ART was not assessed by sub-population due to lack of data. |
| 317 | |
| 318 | DISCUSSION |
| 319 | Leveraging the Rwanda cohort of CA-IeDEA and other nationally representative data, we |
| 320 | developed and calibrated the CA-IeDEA HIV policy model that will inform policy solutions for |
| 321 | equitably achieving global targets. Based on 50 best-fitting sets of model parameters, we found |
| 322 | that the policy model has a good fit to HIV epidemic and global goals (i.e., 95-95-95) targets |
| 323 | over the calibration period, with better performance for women than for men for most targets. |

Model performance was acceptable for the number on ART in recent years and percentage
virally suppressed among adults 15–64 years.

326 Across HIV epidemic and global goals targets, we found that model projections for 327 women outperformed those for men in most cases. This could be explained by greater 328 uncertainty in model parameters for men than for women [54, 55]. For example, among men, 329 model projections for HIV incidence were consistently towards the lower bound of the target 330 confidence intervals, but increasingly overestimated HIV prevalence over the calibration period. 331 This could result from model parameters that overestimate the proportion of condom use among 332 men, which results in underestimation of the probability of HIV transmission, lower projected 333 HIV incidence and higher HIV prevalence. In our model, the parameters for the proportion of 334 men using condoms were based on self-reported condom use [29-31]. Self-reported condom use 335 may be affected by social desirability bias, a type of response bias suggesting respondents may 336 answer questions in a way that is likely to be viewed more favorably [56]. In this case, the 337 socially desirable response is to report consistent condom use with sexual partners. Men have 338 been found to consistently report higher levels of condom use compared to women's reporting of 339 condom use by their male partners [57], suggesting overreporting among men. Improved data 340 quality can reduce uncertainty in parameters and improve model performance.

For HIV epidemic indicators, namely HIV prevalence, we found that model fit later in the calibration period (2019) was not as good as earlier in the calibration period (2005–2015). A possible explanation is uncertainty in HIV prevalence targets because they come from two independent data sources, variation in the number of targets available for a given data source and differences in methodologic approach across sources. That is, three targets came from DHS (2005, 2010, 2015), while one target came from PHIA (2019). This resulted in higher weight of

347 DHS targets during the model calibration process. This resultant weighting is notable because the 348 DHS and PHIA data used different sample selection approaches to estimate HIV prevalence. 349 DHS data estimated HIV prevalence among Rwandans who voluntarily received anonymous 350 HIV testing (i.e., opt-in approach) [31]; in contrast, PHIA data estimated HIV prevalence among 351 individuals who did not refuse to receive their HIV testing result (i.e., opt-out approach) [1]. 352 Evidence suggests that opt-out HIV testing has a higher uptake than opt-in testing [58], which 353 implies a less biased sample for PHIA estimates. Ultimately, the estimate from PHIA is less 354 likely to follow the model's HIV prevalence trend fitted to DHS data. Future work to consider 355 data quality in model calibration targets—an area understudied in the literature—is warranted. 356 While the model generally had a good fit to HIV epidemic and global goals calibration 357 targets, the model did not perform as well for other targets. For percentage virally suppressed 358 among diagnosed adults, for example, a possible explanation is potential bias in the targets. That 359 is, the targets were calculated and reported conditional on self-reported awareness of HIV-360 positive status. However, evidence suggests that underreporting of awareness of HIV-positive 361 status in observational data occurs consistently across countries, ranging from 3% (Eswatini) to 362 47% (Nigeria) [59-62]. Our model's worse fit to these targets may reflect potential biases in the 363 data or, alternatively, may reveal plausible trends in care engagement in this setting. 364 Model fit for number on ART, 15-44 years, similarly did not perform as well as for HIV 365 epidemic or global goals indicators, although fit was better later in the calibration period. Worse 366 performance could be due in part to the aggregated data available for this calibration target: That 367 is, available data report all Rwandans on ART, including pediatric cases. Although we adjusted 368 the targets based on the age distribution of Rwandans on ART, the age distribution we applied

| 369 | was available only in the most recent data year for this target (2021) [63]. Model fit could be |
|-----|---|
| 370 | improved with additional data that disaggregate the information by age and time. |
| 371 | The CA-IeDEA HIV policy model, designed explicitly to assess potential policy |
| 372 | solutions for equitably achieving global targets in Rwanda, extends existing mathematical |
| 373 | models applied in the Rwandan context. Our model includes two broad dimensions (disease |
| 374 | progression and the HIV care continuum) versus only a single dimension (care continuum) as in |
| 375 | the Nsanzimana model [6]. Including these two dimensions better account for differences in |
| 376 | health policy (e.g., ART initiation criteria) over time, improved model fit to historical data and |
| 377 | increased potential to capture more nuanced differences in future health outcomes overall and for |
| 378 | different sub-populations. Further, our model included 25 sub-populations defined by age, |
| 379 | gender, risk and sub-national unit versus risk only (as in the Nsanzimana model) or age and |
| 380 | gender only (as in the Bendavid model) [6, 8]. The CA-IeDEA HIV policy model's structure will |
| 381 | allow for more nuanced assessment of programmatic needs to achieve country-specific goals and |
| 382 | do so equitably across sub-populations [31]. |
| 383 | The CA-IeDEA HIV policy model also adds to existing mathematical modeling literature |
| 384 | methodologically. Systematic reviews find that a large proportion of modeling studies do not |
| 385 | specify quantitative GoF measures for model calibration [64, 65]. Indeed, the two existing |
| 386 | modeling studies in Rwanda provide no description of GoF measures. While our approach, |
| 387 | percent deviation, has been used less commonly [65], it aligns with modeling studies that use |
| 388 | calibration targets with disparate scales [50]. That is, a percent deviation GoF measure allows for |
| 389 | inclusion of a variety of calibration targets and from multiple data sources, as in Rwanda, in |
| 390 | order to improve model performance [44]. |
| 391 | Limitations |

392 Our model is not without limitations. First, we did not explicitly include men who have 393 sex with men (MSM) as a sub-population in our model, although model revisions to include this 394 sub-population are in development. Second, we assumed no urban-rural sexual contacts. While 395 this may lead to underestimation of HIV incidence over time due to urbanization and increased 396 mobility in Rwanda [66], the model had a good fit to HIV incidence indicators over the 397 calibration period. Third, in deriving model parameters, we did not explicitly account for 398 potential bias inherent in the observational data. However, in the calibration process, we 399 addressed this limitation by allowing for full variation in the baseline parameter values derived 400 from the observational data. Fourth, we did not specifically capture either in the model or in the 401 model parameters social and health system contexts (e.g., women empowerment, trust in HIV 402 services) in Rwanda [67], which might limit the accuracy of model projections. However, by 403 allowing for variation in parameter values, we likely account for the effects of social and health 404 system factors on HIV epidemic, global goals and other indicators.

405 Fifth, calibration targets for certain sub-populations (e.g., adolescent girls and young 406 women, female sex workers) were limited given data unavailability. However, model fit can be 407 re-assessed as population-based data emerge for these sub-populations. Lastly, our GoF measure, 408 i.e., percent deviation, may overweight calibration targets with small baseline values because 409 small differences between projected and calibrated values can translate into a large percentage 410 differences. Similarly, our GoF measure did not capture differences in the quality of calibration 411 target data. To minimize such effects, we integrated an additional model performance measure 412 on the percentage of model projections within calibration target CIs, when available.

413

414 CONCLUSIONS

- 415 The calibrated CA-IeDEA HIV policy model is ideally positioned to examine the policy
- 416 solutions that will propel Rwanda not only toward ending the HIV epidemic as a public health
- 417 threat, but doing so equitably. As mathematical modeling continues to be used to inform
- 418 programmatic planning, there is a critical need for high quality population-based calibration
- 419 target data over time, as well as development of approaches to measure and adjust for calibration
- 420 target quality and refine GoF measures when relying on disparate scales.

421 ACKNOWLEDGEMENTS

422 Members of Central Africa IeDEA are:

423 Nimbona Pélagie, Association Nationale de Soutien aux Séropositifs et Malade du Sida (ANSS), 424 Burundi; Patrick Gateretse, Jeanine Munezero, Valentin Nitereka, Annabelle Nivongabo, 425 Zacharie Ndizeve, Christella Twizere, Théodore Nivongabo, Centre National de Référence en 426 Matière de VIH/SIDA, Burundi; Hélène Bukuru, Thierry Nahimana, Martin Manirakiza, Centre 427 de Prise en Charge Ambulatoire et Multidisciplinaire des PVVIH/SIDA du Centre Hospitalo-428 Universitaire de Kamenge (CPAMP-CHUK), Burundi; Patrice Barasukana, Hélène Bukuru, 429 Martin Manirakiza, Zacharie Ndizeye, CHUK/Burundi National University, Burundi; Jérémie 430 Biziragusenyuka, Ella Ange Kazigamwa, Centre de Prise en Charge Ambulatoire et 431 Multidisciplinaire des PVVIH/SIDA de l'Hôpital Prince Régent Charles (CPAMP-HPRC). 432 Burundi; Caroline Akoko, Ernestine Kesah, Esther Neba, Denis Nsame, Vera Veyieeneneng, 433 Bamenda Regional Hospital, Cameroon; Bazil Ageh Ajeh, Rogers Ajeh, Dan Ebai Ashu, Eta 434 Atangba, Christelle Tayomnou Deussom, Peter Vanes Ebasone, Ernestine Kendowo, Clarisse 435 Lengouh, Gabriel Mabou, Sandra Mimou Mbunguet, Judith Nasah, Nicoline Ndiforkwah, Marc 436 Lionel Ngamani, Eric Ngassam, George Njie Ngeke, Clenise Ngwa, Anyangwa Sidonie, Clinical 437 Research Education and Consultancy (CRENC), Cameroon; Anastase Dzudie, CRENC and 438 Douala General Hospital, Cameroon; Djenabou Amadou, Joseph Mendimi Nkodo, Eric Pefura 439 Yone, Jamot Hospital, Cameroon; Annereke Nyenti, Phyllis Fon, Mercy Ndobe, Priscilia Enow, 440 Limbe Regional Hospital, Cameroon; Catherine Akele, Akili Clever, Faustin Kitetele, Patricia 441 Lelo, Kalembelembe Pediatric Hospital, Democratic Republic of Congo; Nana Mbonze, Guy 442 Koba, Martine Tabala, Cherubin Ekembe, Didine Kaba, Kinshasa School of Public Health, 443 Democratic Republic of Congo; Jean Paul Nzungani, Simon Kombela, Dany Lukeba, Sangos 444 plus/Bomoi, Democratic Republic of Congo; Mattieu Musiku, Clement Kabambayi, Job 445 Nsoki, Hopital de Kabinda, Democratic Republic of Congo; Merlin Diafouka, Martin Herbas 446 Ekat, Dominique Mahambou Nsonde, CTA Brazzaville, Republic of Congo; Ursula Koukha, 447 Adolphe Mafoua, Massamba Ndala Christ, CTA Pointe-Noire, Republic of Congo; Jules 448 Igirimbabazi, Nicole Ayinkamiye, Bethsaida Health Center, Rwanda: Providance Uwineza, 449 Emmanuel Ndamijimana, Busanza Health Center, Rwanda; Jean Marie Vianney Barinda, Marie 450 Louise Nyiraneza, Gahanga Health Center, Rwanda; Marie Louise Nyiransabimana, Liliane 451 Tuyisenge, Gikondo Health Center, Rwanda; Catherine Kankindi, Christian Shyaka, Kabuga 452 Health Center, Rwanda; Bonheur Uwakijijwe, Marie Grace Ingabire, Kicukiro Health Center, 453 Rwanda; Beltirde Uwamariya, Jules Ndumuhire, Masaka Health Center, Rwanda; Gerard 454 Bunani, Fred Muyango, Nyagasambu Health Center, Rwanda; Yvette Ndoli, Oliver Uwamahoro, 455 Nyarugunga Health Center, Rwanda; Eugenie Mukashyaka, Rosine Feza, Shyorongi Health 456 Center, Rwanda; Chantal Benekigeri, Jacqueline Musaninyange, WE-ACTx for Hope Clinic, 457 Rwanda; Josephine Gasana, Charles Ingabire, Jocelyne Ingabire, Faustin Kanyabwisha, Gallican 458 Kubwimana, Fabiola Mabano, Jean Paul Miyumbi, Benjamin Muhoza, Athanase Munyaneza, 459 Gad Murenzi, Francoise Musabyimana, Allelluia Giovanni Ndabakuranye, Fabienne 460 Shumbusho, Patrick Tuvisenge, Francine Umwiza, Research for Development (RD Rwanda) and 461 Rwanda Military Hospital, Rwanda; Jules Kabahizi, Janviere Mutamuliza, Boniface 462 Nsengiyumva, Ephrem Rurangwa, Rwanda Military Hospital, Rwanda; Eric Remera, Gallican 463 Nshogoza Rwibasira, Rwanda Biomedical Center, Rwanda. Adebola Adedimeji, Kathryn 464 Anastos, Jean Claude Dusingize, Lynn Murchison, Viraj Patel, Jonathan Ross, Marcel

- 465 Yotebieng, Natalie Zotova, Albert Einstein College of Medicine, USA; Ryan Barthel, Ellen
- 466 Brazier, Heidi Jones, Elizabeth Kelvin, Denis Nash, Saba Qasmieh, Chloe Teasdale, Institute for
- 467 Implementation Science in Population Health, Graduate School of Public Health and Health
- 468 Policy, City University of New York (CUNY), USA; Batya Elul, Columbia University, USA;
- 469 Xiatao Cai, Don Hoover, Hae-Young Kim, Chunshan Li, Qiuhu Shi, Data Solutions, USA;
- 470 Kathryn Lancaster, The Ohio State University, USA; Mark Kuniholm, University at Albany,
- 471 State University of New York, USA; Andrew Edmonds, Angela Parcesepe, Jess Edwards,
- 472 University of North Carolina at Chapel Hill, USA; Olivia Keiser, University of Geneva;
- 473 Stephany Duda; Vanderbilt University School of Medicine, USA; April Kimmel, Virginia
- 474 Commonwealth University School of Medicine, USA.
- 475

476 **REFERENCES**

- 477 1. Rwanda Biomedical Center (RBC). Rwanda population-based HIV impact assessment
- 478 (RPHIA) 2018–2019: Final Report 2020 [cited 2024 July 1]. Available from:
- 479 <u>https://phia.icap.columbia.edu/wp-content/uploads/2020/11/RPHIA-Final-Report_Web.pdf.</u>
- 480 2. National Institute of Statistics of Rwanda (NISR) [Rwanda], Ministry of Health (MOH)
- 481 [Rwanda], ICF International. Demographic and Health Survey, 2019-2020: Supplemental
- 482 report for HIV prevalence 2023 [cited 2024 July 1]. Available from:
- 483 <u>https://dhsprogram.com/pubs/pdf/FR370/FR370s.pdf</u>.
- 484 3. Joint United Nations Programme on HIV/AIDS. Global AIDS Strategy 2021-2026 End
- 485 Inequalities. End AIDS. 2021 [cited 2024 July 1]. Available from:
- 486 <u>https://www.unaids.org/sites/default/files/media_asset/global-AIDS-strategy-2021-</u>
- 487 <u>2026 en.pdf</u>.
- 488 4. Rwanda Biomedical Center (RBC). HIV, STIs and viral hepatitis programs annual report
 489 2022-2023 2023 [cited 2024 July 1]. Available from:
- 490 <u>https://www.rbc.gov.rw/fileadmin/user_upload/report23/HIV%20Annual%20report%20202</u>
- 491 <u>2%20-2023.pdf</u>.
- 492 5. Borquez A, Cori A, Pufall EL, Kasule J, Slaymaker E, Price A, et al. The incidence patterns
- 493 model to estimate the distribution of new HIV infections in Sub-Saharan Africa:
- development and validation of a mathematical model. PLoS Med. 2016;13(9):e1002121.
- 495 6. Nsanzimana S, Mills EJ, Harari O, Mugwaneza P, Karita E, Uwizihiwe JP, et al. Prevalence
- 496 and incidence of HIV among female sex workers and their clients: modelling the potential
- 497 effects of intervention in Rwanda. BMJ Glob Health. 2020;5(8):e002300.

- 498 7. Banzi W, Rotich TK, Ntaganda JM. Mathematical Modelling of the effects of peer-
- 499 educators' campaign on the dynamics of HIV/AIDS in Rwanda. Rwanda Journal of
- 500 Engineering, Science, Technology and Environment. 2019;2(1).
- 8. Bendavid E, Stauffer D, Remera E, Nsanzimana S, Kanters S, Mills EJ. Mortality along the
- 502 continuum of HIV care in Rwanda: A model-based analysis. BMC Infect Dis. 2016;16.
- 503 9. Stover J, Glaubius R, Teng Y, Kelly S, Brown T, Hallett TB, et al. Modeling the
- 504 epidemiological impact of the UNAIDS 2025 targets to end AIDS as a public health threat
- 505 by 2030. PLoS Med. 2021;18(10):e1003831.
- 506 10. Adedimeji AA, Hoover DR, Shi Q, Kim H-Y, Brazier E, Ross J, et al. Trends in
- 507 demographic and clinical characteristics and initiation of antiretroviral therapy among adult
- 508 patients enrolling in HIV care in the Central Africa International epidemiology Database to
- 509 Evaluate AIDS (CA-IeDEA) 2004 to 2018. J Int AIDS Soc. 2021;24(6):e25672.
- 510 11. Central Africa International epidemiology Databases to Evaluate AIDS [cited 2024 July 1].
 511 Available from: https://ca-iedea.org/.
- 512 12. Institut National de la Statistique (INSR) [Rwanda], ORC Macro. Rwanda Demographic
- and Health Survey 2005 [Dataset] Calverton, Maryland, USA: Institut National de la
- 514 Statistique and ORC Macro [Producers]; ICF [Distributor], 2006 [cited 2020 Febuary 24].
- 515 Available from: <u>http://dhsprogram.com/pubs/pdf/FR183/FR183.pdf</u>.
- 516 13. National Institute of Statistics (NISR) [Rwanda], Ministry of Health (MOH) [Rwanda], ICF
- 517 International. Rwanda Demographic and Health Survey 2010 [Dataset] Calverton,
- 518 Maryland, USA: National Institute of Statistics, Ministry of Health, ICF International
- 519 [Producers]; ICF [Distributor], 2012 [cited 2020 August 24]. Available from:
- 520 <u>http://dhsprogram.com/pubs/pdf/FR259/FR259.pdf</u>.

| 521 | 14. | National | Institute | of Statistics | [Rwanda] | , Ministr | y of Finance | and Economic |
|-----|-----|----------|-----------|---------------|----------|-----------|--------------|--------------|
|-----|-----|----------|-----------|---------------|----------|-----------|--------------|--------------|

- 522 Planning[Rwanda], Ministry of Health[Rwanda], ICF International. Rwanda Demographic
- and Health Survey 2014-15 [Dataset] Kigali, Rwanda: National Institute of Statistics,
- 524 Ministry of Finance and Economic Planning, Ministry of Health, and ICF International
- 525 [Producers]; ICF [Distributor], 2016 [cited 2024 August 24]. Available from:
- 526 <u>http://dhsprogram.com/pubs/pdf/FR316/FR316.pdf</u>.
- 527 15. The World Bank. Population estimates and projections 2020 [cited 2024 July 2]. Available
- 528 from: https://datacatalog.worldbank.org/dataset/population-estimates-and-projections.
- 529 16. Kimmel AD, Charles M, Deschamps M-M, Severe P, Edwards AM, Johnson WD, et al.
- Lives saved by expanding HIV treatment availability in resource-limited settings: the
 example of Haiti. J Acquir Immune Defic Syndr. 2013;63(2):p e40-e8.
- 532 17. Holmes CB, Wood R, Badri M, Zilber S, Wang B, Maartens G, et al. CD4 decline and
- 533 incidence of opportunistic infections in Cape Town, South Africa: implications for

534 prophylaxis and treatment. J Acquir Immune Defic Syndr. 2006;42(4):p 464-9.

- 535 18. World Health Organization. Antiretroviral therapy for HIV infection in adults and
- adolescents: recommendations for a public health approach 2006 [cited 2024 July 2].

537 Available from: https://iris.who.int/handle/10665/43554.

- 538 19. World Health Organization. Antiretroviral therapy for HIV infection in adults and
- adolescents: recommendations for a public health approach 2010 [cited 2024 July 2].
- 540 Available from: <u>https://www.who.int/publications/i/item/9789241599764</u>.
- 541 20. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for
- 542 treating and preventing HIV infection: recommendations for a public health approach 2013

- 543 [cited 2024 July 2]. Available from:
- 544 https://www.who.int/publications/i/item/9789241505727.
- 545 21. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for
- 546 treating and preventing HIV infection: recommendations for a public health approach 2nd
- 647 edition 2016 [cited 2024 July 02]. Available from:
- 548 https://www.who.int/publications/i/item/9789241549684.
- 549 22. Rwanda Biomedical Center (RBC). National guidelines for prevention and management of
- 550 HIV, STIs & other blood borne infections. Edition 2013 2013 [cited 2024 July 2]. Available
- 551 from: <u>https://www.rbc.gov.rw/index.php?id=696</u>.
- 552 23. Rwanda Biomedical Center (RBC). National guidelines for prevention and management of
- 553 HIV and STIs. Edition 2016 2016 [cited 2024 July 1]. Available from:
- 554 <u>https://www.rbc.gov.rw/index.php?id=696</u>.
- 555 24. Rwanda Biomedical Center (RBC). Guidelines for HIV prevention, treatment and care in
- 556 Rwanda. Edition 2022 2022 [cited 2024 July 2]. Available from:
- 557 <u>https://www.rbc.gov.rw/index.php?id=696</u>.
- 558 25. Ross J, Sinayobye JdA, Yotebieng M, Hoover DR, Shi Q, Ribakare M, et al. Early outcomes
- after implementation of treat all in Rwanda: an interrupted time series study. J Int AIDS
- 560 Soc. 2019;22(4):e25279.
- 561 26. Nsanzimana S, Remera E, Kanters S, Forrest JI, Ford N, Condo J, et al. Effect of baseline
- 562 cd4 cell count at linkage to HIV care and at initiation of antiretroviral therapy on mortality
- 563 in HIV positive adult patients in Rwanda: A nationwide cohort study. Lancet HIV.
- 564 2015;2(9):e376-e84.

- 565 27. Kimmel AD, Fitzgerald DW, Pape JW, Schackman BR. Performance of a mathematical
- 566 model to forecast lives saved from HIV treatment expansion in resource-limited settings.
- 567 Med Decis Making. 2015;35(2):230-42.
- 568 28. Kerr CC, Stuart RM, Gray RT, Shattock AJ, Fraser-Hurt N, Benedikt C, et al. Optima: a
- 569 model for HIV epidemic analysis, program prioritization, and resource optimization. J
- 570 Acquir Immune Defic Syndr. 2015;69(3):365-76.
- 571 29. Institut National de la Statistique (INSR) [Rwanda], ORC Macro. Rwanda Demographic
- and Health Survey 2005 Calverton, Maryland, USA: INSR and ORC Macro; 2006 [cited
- 573 2024 July 2]. Available from: <u>http://dhsprogram.com/pubs/pdf/FR183/FR183.pdf</u>.
- 574 30. National Institute of Statistics (NISR)[Rwanda], Ministry of Health (MOH)[Rwanda], ICF
- 575 International. Rwanda Demographic and Health Survey 2010 Calverton, Maryland, USA:
- 576 NISR/Rwanda, MOH/Rwanda, and ICF International; 2012 [cited 2024 July 2]. Available
- 577 from: <u>http://dhsprogram.com/pubs/pdf/FR259/FR259.pdf</u>.
- 578 31. National Institute of Statistics [Rwanda], Ministry of Finance and Economic Planning
- 579 [Rwanda], Ministry of Health[Rwanda], ICF International. Rwanda Demographic and
- 580 Health Survey 2014-15 Kigali, Rwanda: National Institute of Statistics of Rwanda, Ministry
- 581 of Finance and Economic Planning/Rwanda, Ministry of Health/Rwanda, and ICF
- 582 International; 2016 [cited 2024 July 2]. Available from:
- 583 <u>http://dhsprogram.com/pubs/pdf/FR316/FR316.pdf</u>.
- 584 32. Ross J, Ribakare M, Remera E, Murenzi G, Munyaneza A, Hoover DR, et al. High levels of
- 585 viral load monitoring and viral suppression under Treat All in Rwanda a cross-sectional
- 586 study. J Int AIDS Soc. 2020;23(6):e25543.

- 587 33. The U.S. President's Emergency Plan for AIDS Relief. Rwanda country operational plan
- 588 (COP/ROP) 2022 strategic direction summary 2022 [cited 2024 July 2]. Available from:
- 589 https://www.state.gov/wp-content/uploads/2022/09/Rwanda-COP22-SDS.pdf.
- 590 34. Mutagoma M, Kayitesi C, Gwiza A, Ruton H, Koleros A, Gupta N, et al. Estimation of the
- 591 size of the female sex worker population in Rwanda using three different methods. Int J
- 592 STD AIDS. 2015;26(11):810-4.
- 593 35. National Institute of Statistics of Rwanda, Ministry of Finance and Economic Planning.
- 594 Fourth population and housing census, Rwanda, 2012. Thematic report: Migration and
- spatial mobility 2014 [cited 2024 July 2]. Available from:
- 596 <u>https://www.statistics.gov.rw/publication/rphc4-thematic-report-migration-and-spatial-</u>
- 597 <u>mobility</u>.
- 598 36. Joint United Nations Programme on HIV/AIDS. Sex workers: Population size estimate:
- 599 UNdata; 2015 [updated 2024 July 3]. 2015 October 21:[Available from:
- 600 <u>http://data.un.org/Data.aspx?d=UNAIDS&f=inID%3A111</u>.
- 601 37. Rwanda Ministry of Health. Behavioral and biological surveillance survey among female
- 602 sex workers, Rwanda 2010: Suevey report 2010 [cited 2024 July 3]. Available from:
- 603 <u>https://rbc.gov.rw/IMG/pdf/behavioral_and_biological_survey_among_female_sex_workers</u>
 604 rwanda 2010.pdf.
- 605 38. Braunstein SL, Umulisa MM, Veldhuijzen NJ, Kestelyn E, Ingabire CM, Nyinawabega J, et
- al. HIV diagnosis, linkage to HIV Care, and HIV risk behaviors among newly diagnosed
- 607 HIV-positive female sex workers in Kigali, Rwanda. J Acquir Immune Defic Syndr.
- 608 2011;57(4):70-6.

- 609 39. Boily M-C, Baggaley RF, Wang L, Masse B, White RG, Hayes RJ, et al. Heterosexual risk
- 610 of HIV-1 infection per sexual act: systematic review and meta-analysis of observational
- 611 studies. Lancet Infect Dis. 2009;9(2):118-29.
- 612 40. Weller SC, Davis-Beaty K. Condom effectiveness in reducing heterosexual HIV
- 613 transmission. Cochrane Database Syst Rev. 2002;(1):CD003255.
- 614 41. Supervie V, Viard JP, Costagliola D, Breban R. Heterosexual Risk of HIV Transmission per
- 615 Sexual Act Under Combined Antiretroviral Therapy: Systematic Review and Bayesian
- 616 Modeling. 2014;59(1):115-22.
- 42. Braunstein SL, Ingabire CM, Geubbels E, Vyankandondera J, Umulisa MM, Gahiro E, et al.
- 618 High burden of prevalent and recently acquired HIV among female sex workers and female
- 619 HIV voluntary testing center clients in Kigali, Rwanda. PloS One. 2011;6(9):e24321.
- 620 PubMed PMID: 21949704.
- 43. Okal DO, Oyaro B, Zeh C, Desai MA, Samandari T, Chen RT, et al. Effect of point-of-care
- 622 CD4 cell count results on linkage to care and antiretroviral initiation during a home-based
- 623 HIV testing campaign: a non-blinded, cluster-randomised trial. Lancet HIV.
- 624 2017;4(9):e393-e401.
- 625 44. Nsanzimana S, Kanters S, Remera E, Forrest JI, Binagwaho A, Condo J, et al. HIV care

626 continuum in Rwanda: A cross-sectional analysis of the national programme. Lancet HIV.

- 627 2015;2(5):e208-e15.
- 45. Rwanda Ministry of Health. National HIV and viral hepatitis annual report 2020-2021 2021
- 629 [cited 2024 July 3]. Available from: <u>https://www.rbc.gov.rw/index.php?id=693</u>.
- 630 46. Rwanda Ministry of Health. Rwanda HIV and AIDS national strategic plan 2013–2018:
- 631 Extension: 2018–2020 2018 [cited 2024 July 3]. Available from:

- https://rbc.gov.rw/fileadmin/user_upload/stra2019/strategie2019/Rwanda%20Strategic%20P
 lan%20for%20HIV%20Extended%20to%202020.pdf.
- 47. Rachlis B, Ochieng D, Geng E, Rotich E, Ochieng V, Maritim B, et al. Evaluating outcomes
- of patients lost to follow-up in a large comprehensive care treatment program in western
- 636 Kenya. J Acquir Immune Defic Syndr. 2015;68(4):e46 e55.
- 637 48. Geng EH, Bwana MB, Muyindike W, Glidden DV, Bangsberg DR, Neilands TB, et al.
- 638 Failure to initiate antiretroviral therapy, loss to follow-up and mortality among HIV-infected
- 639 patients during the pre-ART period in Uganda. J Acquir Immune Defic Syndr.
- 640 2013;63(2):e64 e71.
- 49. Vanni T, Karnon J, Madan J, White RG, Edmunds WJ, Foss AM, et al. Calibrating models
 in economic evaluation: A seven-step approach. Pharmacoeconomics. 2011;29(1):35-49.
- 50. Zang X, Krebs E, Min JE, Pandya A, Marshall BDL, Schackman BR, et al. Development
- and Calibration of a Dynamic HIV Transmission Model for 6 US Cities. Med Decis
 Making. 2020;40(1):3-16.
- 51. Hyndman RJ, Koehler AB. Another look at measures of forecast accuracy. Int J Forecast.
 2006;22(4):679-88.
- 648 52. McKenna MT, Weis JA, Barnes SL, Tyson DR, Miga MI, Quaranta V, et al. A Predictive
- 649 Mathematical Modeling Approach for the Study of Doxorubicin Treatment in Triple
- 650 Negative Breast Cancer. Sci Rep. 2017;7:5725.
- 53. Bastan M, Grösser S, Zadfallah E, editors. Model-based risk assessment to clinical risk
- management policies. The 36th International Conference of the System Dynamics Society,
- 653 Reykjavík, Iceland, System Dynamics Society; 2018.

- 654 54. Anderson RM. The role of mathematical models in the study of HIV transmission and the
 655 epidemiology of AIDS. J Acquir Immune Defic Syndr. 1988;1(3):241-56.
- 656 55. Tolles JL, ThaiBinh Modeling epidemics with compartmental models. JAMA.
- 657 2020;323(24):2515-6.
- 658 56. Krumpal I. Determinants of social desirability bias in sensitive surveys: a literature review.
- 659 Quality & quantity. 2013;47(4):2025-47.
- 57. De Walque D, Kline R. Variations in condom use by type of partner in 13 Sub-Saharan
 African Countries. Stud Fam Plann. 2011;42(1):1-10.
- 58. Soh QR, Oh LYJ, Chow EPF, Johnson CC, Jamil MS, Ong JJ. HIV testing uptake according
- to opt-in, opt-out or risk-based testing approaches: a systematic review and meta-analysis.
- 664 Curr HIV/AIDS Rep. 2022;19(5):375-83.
- 665 59. Mooney AC, Campbell CK, Ratlhagana M-J, Grignon JS, Mazibuko S, Agnew E, et al.
- 666 Beyond social desirability bias: investigating inconsistencies in self-reported HIV testing
- and treatment behaviors among HIV-positive adults in North West Province, South Africa.
- 668 AIDS Behav. 2018;22(7):2368-79.
- 669 60. Xia Y, Milwid RM, Godin A, Boily M-C, Johnson LF, Marsh K, et al. Accuracy of self-
- 670 reported HIV-testing history and awareness of HIV-positive status in four sub-Saharan
- 671 African countries. AIDS. 2021;35(3):503-10.
- 672 61. Jahun I, Ehoche A, Bamidele M, Yakubu A, Bronson M, Dalhatu I, et al. Evaluation of
- 673 accuracy and performance of self-reported HIV and antiretroviral therapy status in the
- 674 Nigeria AIDS Indicator and Impact Survey (2018). PloS One. 2022;17(8):e0273748.

- 675 62. Chasimpha SJD, Mclean EM, Dube A, McCormack V, dos-Santos-Silva I, Glynn JR.
- 676 Assessing the validity of and factors that influence accurate self-reporting of HIV status
- after testing: a population-based study. AIDS. 2020;34(6):931-41.
- 678 63. Nsanzimana S, Remera E, Kanters S, Chan K, Forrest JI, Ford N, et al. Life expectancy
- among HIV-positive patients in Rwanda: A retrospective observational cohort study. Lancet
- 680 Glob Health. 2015;3(3):e169-e77. PubMed PMID: 25701995.
- 681 64. Conrads-Frank A, Jahn B, Bundo M, Sroczynski G, Mühlberger N, Bicher M, et al. A
- 682 systematic review of calibration in population models. Value Health. 2017;20(9):A745.
- 683 65. Hazelbag CM, Dushoff J, Dominic EM, Mthombothi ZE, Delva W. Calibration of
- 684 individual-based models to epidemiological data: A systematic review. PloS Comput Biol.
- 685 2020;16(5):e1007893.
- 686 66. Camlin CS, Charlebois ED. Mobility and its effects on HIV acquisition and treatment
- 687 engagement: recent theoretical and empirical advances. Curr HIV/AIDS Rep.
- 688 2019;16(4):314-23.
- 689 67. Ingabire C, Watnick D, Gasana J, Umwiza F, Munyaneza A, Kubwimana G, et al.
- 690 Experiences of stigma and HIV care engagement in the context of Treat All in Rwanda: a
- 691 qualitative study. BMC Public Health. 2023;23(1):1817.



S



D







Panel A. Number on ART

Panel B. Percent virally suppressed among adults